NCT03347123

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	Epacadostat	Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
DRUG	Nivolumab	Nivolumab at the protocol-specified dose and schedule.
DRUG	Ipilimumab	Ipilimumab at the protocol-specified dose and schedule.
DRUG	Lirilumab	Lirilumab at the protocol-specified dose and schedule.

Timeline

• Start date: 2018-03-21
• Primary completion: 2021-01-29
• Completion: 2021-01-29
• First posted: 2017-11-20
• Last updated: 2022-02-28
• Results posted: 2022-02-28

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study